In last trading session, Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) saw 1.25 million shares changing hands with its beta currently measuring 1.83. Company’s recent per share price level of $2.47 trading at -$0.06 or -2.37% at ring of the bell on the day assigns it a market valuation of $176.02M. That closing price of ZNTL’s stock is at a discount of -631.58% from its 52-week high price of $18.07 and is indicating a premium of 34.82% from its 52-week low price of $1.61.
For Zentalis Pharmaceuticals Inc (ZNTL), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.20. Splitting up the data highlights that, out of 10 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 5 suggested the stock as a Hold whereas 5 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.68 in the current quarter.
Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) trade information
Upright in the red during last session for losing -2.37%, in the last five days ZNTL remained trading in the green while hitting it’s week-highest on Thursday, 02/20/25 when the stock touched $2.47 price level, adding 6.08% to its value on the day. Zentalis Pharmaceuticals Inc’s shares saw a change of -18.48% in year-to-date performance and have moved 14.35% in past 5-day. Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) showed a performance of 9.78% in past 30-days.
Wall Street analysts have assigned a consensus price target of 10 to the stock, which implies a rise of 75.3% to its current value. Analysts have been projecting 4 as a low price target for the stock while placing it at a high target of 55. It follows that stock’s current price would drop -61.94% in reaching the projected high whereas dropping to the targeted low would mean a loss of -61.94% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -50.05% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 44.85% while estimates for its earnings growth in next 5 years are of 19.63%.
Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL)’s Major holders
MATRIX CAPITAL MANAGEMENT COMPANY, LP is the top institutional holder at ZNTL for having 13.96 million shares of worth $57.1 million. And as of 2024-06-30, it was holding 19.6509 of the company’s outstanding shares.
The second largest institutional holder is FMR LLC, which was holding about 8.68 million shares on 2024-06-30. The number of shares represents firm’s hold over 12.2383 of outstanding shares, having a total worth of $35.49 million.
